Stocky turns companies like Infant Bacterial Therapeutics into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Stocky rates Infant Bacterial Therapeutics at 32/100 based on business quality, leadership alignment, valuation.
How safely Infant Bacterial Therapeutics is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for Infant Bacterial Therapeutics:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 32/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Infant Bacterial Therapeutics (IBT-B.ST) shares last traded at kr 80.70, down 0.12% on the day on Stockholm (as of 22 Oct, 07:02 UTC). Prices are in SEK and update through the trading day.
Stocky rates Infant Bacterial Therapeutics (IBT-B.ST) at 32/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation into a single number.
IBT-B.ST's current Stocky Verdict is 32/100, placing it in the "Avoid" band. This composite combines a 24/100 Compounder score, Leadership, 10/100 Moat rating.
Infant Bacterial Therapeutics rates Limited moat (10/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
Leadership Alignment for Infant Bacterial Therapeutics is under analysis. Stocky scores founder tenure, insider ownership, CEO compensation multiple-of-salary, and long-term shareholder value creation.
Infant Bacterial Therapeutics's Resilience Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Infant Bacterial Therapeutics.
Sign up free and unlock the full analysis on IBT-B.ST — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for IBT-B.ST in the app.
